Clinical Efficacy of Clotting Factor Concentrates: Survival, Recovery and Hemostatic Capacity

  • I. M. Nilsson
  • E. Berntorp
Part of the Developments in Hematology and Immunology book series (DIHI, volume 26)


Factor VIII concentrates are necessary for the treatment not only of patients with hemophilia A but also for those with severe von Willebrand’s disease (vWD), especially the type III or the type II variants. Earlier, above all cryoprecipitate, and low and intermediate purity concentrates were used. The intermediate purity concentrates contained 1–3 units of factor VIII clotting activity (FVIII:C) per mg protein, factor VIII itself being only a trace protein. Since 1984, all commercial factor VIII concentrates have been subjected to some form of virus inactivation.In the last years several plasma-derived, superpure factor VIII concentrates have been developed to eliminate the risk of viral transmission, and to reduce other side effects caused by the multiplicity of foreign proteins and alloantigens the concentrates of intermediate purity contain. Clinical trials of recombinant factor VIII have also been started. Correction of the bleeding defect in vWD requires a concentrate containing almost native von Wille rand factor (vWF).


Factor VIII Recombinant Factor Viii Severe Hemophilia Factor Viii Concentrate Recombinant Preparation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nilsson IM, Kirkwood TBL, Barrowcliffe TW. In vivo recovery of factor VIII: A comparison of one-stage and two-stage assay methods. Thromb Haemostas 1979;42:1230–9.Google Scholar
  2. 2.
    Lethagen S, Östergaard H, Nilsson IM. Clinical application of the chromogenic assay of factor VIII in hemophilia A, and different variants of von Willebrand’s disease. Scand J Haematol 1987;37:448–53.CrossRefGoogle Scholar
  3. 3.
    Nilsson IM, Berntorp E, Zettervall O, Dahlbäck B. Non-coagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients. Blood 1990;75:378–83.PubMedGoogle Scholar
  4. 4.
    Laurell CB. Quantitive estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966;15:45–52.PubMedCrossRefGoogle Scholar
  5. 5.
    Ingerslev J. A sensitive ELISA for von Willebrand factor (vWF:Ag).Scand J Clin Lab Invest 1987;47:143–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Zuzel M, Nilsson IM, Åberg M. A method for measuring plasma ristocetin cofactor activity. Thromb Res 1978;12:745–54.PubMedCrossRefGoogle Scholar
  7. 7.
    Lamme S, Wallmark A, Holmberg L, Nilsson IM, Sjögren HO. The use of monoclonal antibodies in measuring factor Vlll/von Willebrand factor.Scand J Clin Lab Invest 1985;45:17–26.PubMedCrossRefGoogle Scholar
  8. 8.
    Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986;43:303–11.PubMedCrossRefGoogle Scholar
  9. 9.
    Bradford MM. A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the protein dye binding. Anal Biochem 1976;72:248–54.PubMedCrossRefGoogle Scholar
  10. 10.
    Allain JP, Verroust F, Soulier JP. In vitro and in vivo characterization of factor VIII preparations. Vox Sang 1980;38:68–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Cinotti S, Boni E, Morfini M. Factor VIII:C potency assay in two rDNA and in plasma derived concentrates. International Symposium on Biotechnology of plasma proteins: Hemostasis, thrombosis and iron proteins. Florence, Italy, April 1990:60(Abstract).Google Scholar
  12. 12.
    Dawson MJ, Kemball-Cook G, Barrowcliffe TW. Assay discrepancies with highly purified factor VIII concentrates. Haemostasis 1989;19:131–7.PubMedGoogle Scholar
  13. 13.
    Barrowcliffe TW, Dawson NJ, Kemball-Cook G. Activated factor VIII in concentrates prepared by monoclonal antibody and recombinant technology.Thromb Haemostas 1989;62:198(Abstract).Google Scholar
  14. 14.
    Fulcher CA, de Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS.Localization of human factor VIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci USA 1985;82:7728–32.PubMedCrossRefGoogle Scholar
  15. 15.
    Lusher JM. Factor VIII concentrates: Matching what you see with what you get. JAMA 1985;254:802–3.PubMedCrossRefGoogle Scholar
  16. 16.
    Ratnoff OD. Factor VIII concentrates. JAMA 1986;255:325–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Messori A, Longo G, Matucci M, Morfini M, Rossi Ferrini PL. Clinical pharmcokinetics of factor VIII in patients with classic hemophilia. Clin Pharm 1987;13:365–80.CrossRefGoogle Scholar
  18. 18.
    Nilsson IM. Clinical characteristics of the factor VIII concentrates. In:Smit Sibinga CTh, Das PC, Seidl S (eds). Plasma fractionation and blood transfusion. Boston, Dordrecht, Lancaster: Martinus Nijhoff Publishers,1985: 197–209.CrossRefGoogle Scholar
  19. 19.
    Berntorp E, Nilsson IM. Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates. Eur J Haematol 1988;40:205–14.PubMedCrossRefGoogle Scholar
  20. 20.
    Matucci M, Messori A, Donati-Cori G, et al. Kinetic evaluation of four factor VIII concentrates by model-independent methods. Scand J Haematol 1985;34:22–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Longo G, Matucci M, Messori A, Morfini M, Rossi-Ferrini P. Pharmaco-kinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods. Thromb Res 1986;42:471–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Brettler DB, Forsberg AD, Levine PH, Petillo J, Lamon K, Sullivan JL. Factor VIILC concentrate purified from plasma using monoclonal antibodies:Human studies. Blood 1989;73:1859–63.PubMedGoogle Scholar
  23. 23.
    White G, McMillan C, Courter S, Gomperts E and the Recombinate Collaborative Group. Safety and efficacy of antihemophilic factor (recombinant) in hemophilia A patients. Abstract book XIX International Congress of the World Federation of Hemophilia, Washington DC, 1990:25(Abstract 85).Google Scholar
  24. 24.
    Holmberg L, Nilsson IM. Von Willebrand disease. Clin Haematol 1985;14: 461–88.PubMedGoogle Scholar
  25. 25.
    Berntorp E, Nilsson IM. Use of high-purity factor VIII concentrate (Hemate P) in von Willebrand’s disease. Vox Sang 1989;56:212–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Mazurier C, de Romeuf C, Parquet-Gernez A, Goudemand M. In vitro and in vivo characterization of a high-purity, solvent/detergent-treated factor VIII concentrate: Evidence for its therapeutic efficacy in von Willebrand’s disease. Eur J Haematol 1989;43:7–14.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1991

Authors and Affiliations

  • I. M. Nilsson
  • E. Berntorp

There are no affiliations available

Personalised recommendations